In a report released today, Lorenzo Biasio from Credit Suisse maintained a Hold rating on Pfizer (PFE), with a price target of $41.30. The company’s shares closed last Wednesday at $38.45.
Biasio has an average return of 9.1% when recommending Pfizer.
According to TipRanks.com, Biasio is ranked #708 out of 6873 analysts.
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $41.88, which is an 8.9% upside from current levels. In a report issued on July 23, Merrill Lynch also maintained a Hold rating on the stock with a $38.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $40.97 and a one-year low of $27.88. Currently, Pfizer has an average volume of 31.55M.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
